Catalyst Brief

← Calendar

Readoutin 135d

AbbVie — Mirvetuximab soravtansine plus Bevacizumab

Phase 3 primary completion: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer.

Date
Apr 2027
Type
Readout
Indication
Ovarian Cancer

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from AbbVie

  1. Mar2027
    Readoutin 104d
    AbbVie — Upadacitinib
    Phase 3 primary completion: Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus.
  2. Mar2027
    Readoutin 104d
    AbbVie — Risankizumab SC
    Phase 3 primary completion: A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease..
  3. Dec2026
  4. Dec2026
    Readoutin 14d
    AbbVie — Lutikizumab
    Phase 3 primary completion: A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa.